DKSH Stock Analysis: DKSH Holding | SW
Consulting Services | SW, Switzerland | Market Cap: 4.448m CHF | 12M Return: 36.2% | CH0126673539 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.35M
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DKSH Holding AG is a Swiss-based market expansion services provider operating across Thailand, Greater China, Malaysia, Singapore, and the broader Asia Pacific region. The company offers a comprehensive suite of services including sourcing, market insights, marketing, sales, e-commerce, distribution, logistics, and after-sales support, helping international and local brands penetrate and grow in Asian markets.
DKSH operates through four segments: Healthcare, Consumer Goods, Performance Materials, and Technology. The Healthcare segment focuses on pharmaceuticals, consumer health, OTC products, and medical devices, while Consumer Goods covers FMCG, food services, luxury goods, and cosmetics. Performance Materials supplies specialty chemicals and ingredients for industries such as personal care, food and beverage, and industrial applications. The Technology segment provides capital investment goods and analytical instruments across sectors including semiconductors, infrastructure, agriculture, and hospitality.
Founded in 1865 and headquartered in Zurich, DKSH functions as an outsourced go-to-market partner for brands lacking their own distribution infrastructure in Asia. Its business model is essentially that of a third-party distribution and marketing services provider, bridging manufacturers with fragmented retail and B2B networks across emerging Asian markets.
- Healthcare segment expansion drives growth across Asian markets
- Consumer Goods segment exposed to China luxury spending weakness
- Asian currency depreciation pressures Swiss franc reported margins
| Net Income: 212.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.22 > 1.0 |
| NWC/Revenue: 10.39% < 20% (prev 9.17%; Δ 1.21% < -1%) |
| CFO/TA 0.06 > 3% & CFO 339.3m > Net Income 212.2m |
| Net Debt (506.8m) to EBITDA (456.4m): 1.11 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.0m) vs 12m ago -3.13% < -2% |
| Gross Margin: 6.08% > 18% (prev 9.40%; Δ -3.32% > 0.5%) |
| Asset Turnover: 201.5% > 50% (prev 207.6%; Δ -6.05% > 0%) |
| Interest Coverage Ratio: 9.40 > 6 (EBIT TTM 302.6m / Interest Expense TTM 32.2m) |
| A: 0.21 (Total Current Assets 4.16b - Total Current Liabilities 3.02b) / Total Assets 5.55b |
| B: 0.36 (Retained Earnings 2.02b / Total Assets 5.55b) |
| C: 0.06 (EBIT TTM 302.6m / Avg Total Assets 5.47b) |
| D: 0.45 (Book Value of Equity 1.71b / Total Liabilities 3.78b) |
| Altman-Z'' = 3.39 = A |
| DSRI: 1.29 (Receivables 2.26b/1.78b, Revenue 11.0b/11.2b) |
| GMI: 1.55 (GM 9.40% / 6.08%) |
| AQI: 1.00 (AQ_t 0.19 / AQ_t-1 0.19) |
| SGI: 0.99 (Revenue 11.0b / 11.2b) |
| TATA: -0.02 (NI 212.2m - CFO 339.3m) / TA 5.55b) |
| Beneish M = -2.30 (Cap -4..+1) = BBB |
As of September 27, 2026, the stock is trading at CHF 68.90 with a total of 84,132 shares traded. Over the past week, the price has changed by +4.87%, over one month by +5.67%, over three months by +10.95% and over the past year by +36.22%.
Current recommended Stop Loss: 66.40 (which is 3.6% or 2.4 ATR below the current price).
DKSH Holding has no consensus analysts rating.
P/E Trailing = 20.9816
P/E Forward = 16.129
P/S = 0.4029
P/B = 2.594
Revenue TTM = 11.0b CHF
EBIT TTM = 302.6m CHF
EBITDA TTM = 456.4m CHF
Long Term Debt = 468.2m CHF (from longTermDebt, last quarter)
Short Term Debt = 103.1m CHF (from shortTermDebt, last quarter)
Debt = 1.01b CHF (from shortLongTermDebtTotal, last quarter) + Leases 248.0m
Net Debt = 506.8m CHF (calculated: Debt 1.01b - CCE 503.7m)
Enterprise Value = 4.96b CHF (4.45b + Debt 1.01b - CCE 503.7m)
Interest Coverage Ratio = 9.40 (Ebit TTM 302.6m / Interest Expense TTM 32.2m)
EV/FCF = 16.06x (Enterprise Value 4.96b / FCF TTM 308.6m)
FCF Yield = 6.23% (FCF TTM 308.6m / Enterprise Value 4.96b)
FCF Margin = 2.80% (FCF TTM 308.6m / Revenue TTM 11.0b)
Net Margin = 1.93% (Net Income TTM 212.2m / Revenue TTM 11.0b)
Gross Margin = 6.08% ((Revenue TTM 11.0b - Cost of Revenue TTM 10.4b) / Revenue TTM)
Gross Margin QoQ = 6.52% (prev 5.65%)
Tobins Q-Ratio = 0.89 (Enterprise Value 4.96b / Total Assets 5.55b)
Interest Expense / Debt = 3.19% (Interest Expense 32.2m / Debt 1.01b)
Taxrate = 27.98% (85.4m / 305.2m)
NOPAT = 217.9m (EBIT 302.6m * (1 - 27.98%))
Current Ratio = 1.38 (Total Current Assets 4.16b / Total Current Liabilities 3.02b)
Debt / Equity = 0.59 (Debt 1.01b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 1.11 (Net Debt 506.8m / EBITDA 456.4m)
Debt / FCF = 1.64 (Net Debt 506.8m / FCF TTM 308.6m)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.88% (Net Income 212.2m / Total Assets 5.55b)
RoE = 12.23% (Net Income TTM 212.2m / Total Stockholder Equity 1.73b)
RoCE = 13.74% (EBIT 302.6m / Capital Employed (Equity 1.73b + L.T.Debt 468.2m))
RoIC = 10.21% (NOPAT 217.9m / Invested Capital 2.13b)
WACC = 6.45% (E(4.45b)/V(5.46b) * Re(7.39%) + D(1.01b)/V(5.46b) * Rd(3.19%) * (1-Tc(0.28)))
Discount Rate = 7.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -67.84 | Cagr: -1.51%
[DCF] Terminal Value 76.36% ; FCFF base≈300.2m ; Y1≈319.7m ; Y5≈381.1m
[DCF] Fair Price = 82.26 (EV 5.86b - Net Debt 506.8m = Equity 5.35b / Shares 65.0m; r=8.35% [WACC [floored]]; 5y FCF grow 7.34% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 23.23 | Revenue CAGR: 0.22% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.68 | Chg30d=+0.84% | Revisions=-22% | GrowthEPS=+9.8% | GrowthRev=+1.3%
EPS next Year (2027-12-31): EPS=4.02 | Chg30d=+0.21% | Revisions=-17% | GrowthEPS=+9.1% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -25% (up=3, down=6)